Dalton Maag Challenges OEM Font Status Quo with MetricsMatch
3.9.2025 07:00:00 CEST | Business Wire | Press Release
Dalton Maag, the independent typeface design studio known for its high-performance library fonts and custom typefaces for global brands, today launched MetricsMatch – a font solution for Original Equipment Manufacturers (OEMs). The new range provides a cost-effective, high-quality alternative to the industry-standard font sets embedded in consumer electronics, printers, and other devices.
For years, OEMs have expressed frustration with current licensing models, citing high costs, limited flexibility, and vendor lock-in. MetricsMatch directly addresses these challenges with open pricing, fair licensing, and customization options, introducing competition to the market.
At the heart of MetricsMatch is metrics compatibility, which enables the seamless substitution of fonts, reducing integration effort and accelerating time-to-market for established players and new entrants.
“We've heard the frustrations of manufacturers who feel trapped by the current licensing landscape,” said David Marshall, Managing Director of Dalton Maag. “Opaque pricing, legacy products, and restrictive terms have been holding OEMs back. We want MetricsMatch to be a better way forward for these industry-standard font sets.”
“Our studio has always been about quality and independence – and MetricsMatch is no exception,” added Lukas Paltram, Executive Creative Director at Dalton Maag. “We’ve applied the same rigour and attention to detail that we bring to every client project, ensuring that OEMs no longer have to compromise between technical performance and design integrity.”
MetricsMatch launches today with five font sets: consumer computing, PDF rendering, and DVB, MPEG-4, and ATSC closed captions and subtitles. Resident font sets for printer imaging, including 171 fonts to support PCL and PostScript emulation, are in development and scheduled for release in 2026.
Key benefits of MetricsMatch include:
- Open Pricing: Transparent, predictable costs with no hidden fees.
- Fair Licensing: Flexible terms that support innovation and product evolution, without renegotiation.
- Drop-In Replacements: Dalton Maag designs adapted to industry-standard metrics, preserving line endings and layout.
- Standards Compliance: Conformance with industry and ISO standards.
- Exceptional Quality: World-class type design optimized for embedded devices.
- Customization Options: Including naming rights to support product branding.
By combining meticulous design with a proven toolchain, MetricsMatch delivers high-performance font sets, empowering manufacturers with the quality, flexibility, and fairness needed to break free from supplier lock-in while creating a seamless user experience.
For more about MetricsMatch and the technologies it supports, visit daltonmaag.com/metricsmatch
About Dalton Maag
Dalton Maag is an independent typeface design studio with a global reputation for creating and engineering high-performance typefaces. With a multicultural, international team, the London-based studio designs custom and retail fonts for corporate identities, branding, and user interfaces. Its client list includes many of the world's most recognizable brands.
Trademarks
PostScript is a registered trademark of Adobe Inc. ATSC is a registered trademark of the Advanced Television Systems Committee Inc. DVB is a registered trademark of the DVB Project. PCL is a registered trademark of HP Inc. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250902922164/en/
Contacts
Media Contact
Richard Bailey
+44 3334443602
press@daltonmaag.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom